• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Verastem, Inc. - Common Stock (NQ:VSTM)

    7.750 +0.300 (+4.03%)
    Delayed Quote Updated: 3:00 PM EDT, Oct 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Verastem, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    News headline image
    Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III ↗
    Verastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma,... 
    Via MarketBeat
    News headline image
    Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
    From Verastem Oncology
    Via Business Wire
    News headline image
    VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
    From Verastem Oncology
    Via Business Wire
    Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
    Via Chartmill
    News headline image
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright ↗
    Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated... 
    Via MarketBeat
    News headline image
    Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Participate in Upcoming September Investor Conferences
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem (VSTM) Q2 2026 Earnings Call Transcript ↗
    Revenue surged on CO-PACK launch as cash runway extends into late 2027. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Verastem Q2 Earnings Call Highlights ↗
    Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Verastem Oncology
    Via Business Wire
    News headline image
    VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Present at Jefferies Healthcare Conference
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Oncology to Present at Upcoming Investor Conferences
    From Verastem Oncology
    Via Business Wire
    News headline image
    Verastem Q1 Earnings Call Highlights ↗
    Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Verastem (VSTM) Q1 2026 Earnings Transcript ↗
    Verastem (VSTM) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
    From Verastem Oncology
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.